Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia
Naveen Hegde, Ankit Kumar, Shaweta Kaundal, Lekha Saha, Pankaj Malhotra, Shankar Prinja, Deepesh Lad, Amol Patil
Topics & Concepts
IbrutinibMedicineBendamustineInternal medicineRituximabProgression-free survivalQuality-adjusted life yearOncologyChronic lymphocytic leukemiaCost effectivenessLymphomaLeukemiaChemotherapyRisk analysis (engineering)Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentImmunodeficiency and Autoimmune Disorders